These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 9359721)

  • 1. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.
    Johnson S; Oliver C; Prince GA; Hemming VG; Pfarr DS; Wang SC; Dormitzer M; O'Grady J; Koenig S; Tamura JK; Woods R; Bansal G; Couchenour D; Tsao E; Hall WC; Young JF
    J Infect Dis; 1997 Nov; 176(5):1215-24. PubMed ID: 9359721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9.
    Johnson S; Griego SD; Pfarr DS; Doyle ML; Woods R; Carlin D; Prince GA; Koenig S; Young JF; Dillon SB
    J Infect Dis; 1999 Jul; 180(1):35-40. PubMed ID: 10353858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.
    Power UF; Plotnicky-Gilquin H; Huss T; Robert A; Trudel M; Ståhl S; Uhlén M; Nguyen TN; Binz H
    Virology; 1997 Apr; 230(2):155-66. PubMed ID: 9143271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo.
    Crowe JE; Gilmour PS; Murphy BR; Chanock RM; Duan L; Pomerantz RJ; Pilkington GR
    J Infect Dis; 1998 Apr; 177(4):1073-6. PubMed ID: 9534985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
    Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
    J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo.
    Chargelegue D; Obeid OE; Hsu SC; Shaw MD; Denbury AN; Taylor G; Steward MW
    J Virol; 1998 Mar; 72(3):2040-6. PubMed ID: 9499058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    van Erp EA; van Kasteren PB; Guichelaar T; Ahout IML; de Haan CAM; Luytjes W; Ferwerda G; Wicht O
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28794038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein.
    Plotnicky-Gilquin H; Goetsch L; Huss T; Champion T; Beck A; Haeuw JF; Nguyen TN; Bonnefoy JY; Corvaïa N; Power UF
    J Virol; 1999 Jul; 73(7):5637-45. PubMed ID: 10364313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group.
    Subramanian KN; Weisman LE; Rhodes T; Ariagno R; Sánchez PJ; Steichen J; Givner LB; Jennings TL; Top FH; Carlin D; Connor E
    Pediatr Infect Dis J; 1998 Feb; 17(2):110-5. PubMed ID: 9493805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and Evaluation of the Fully Humanized Monoclonal Antibody GD-mAb Against Respiratory Syncytial Virus.
    Tian P; Wang Y; Liu H; Yang Y; Wu X; Wei H; Chen T
    Front Cell Infect Microbiol; 2019; 9():275. PubMed ID: 31417879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection against respiratory syncytial virus infection by DNA immunization.
    Li X; Sambhara S; Li CX; Ewasyshyn M; Parrington M; Caterini J; James O; Cates G; Du RP; Klein M
    J Exp Med; 1998 Aug; 188(4):681-8. PubMed ID: 9705950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group.
    Sáez-Llorens X; Castaño E; Null D; Steichen J; Sánchez PJ; Ramilo O; Top FH; Connor E
    Pediatr Infect Dis J; 1998 Sep; 17(9):787-91. PubMed ID: 9779762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
    Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
    Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein.
    Malley R; DeVincenzo J; Ramilo O; Dennehy PH; Meissner HC; Gruber WC; Sanchez PJ; Jafri H; Balsley J; Carlin D; Buckingham S; Vernacchio L; Ambrosino DM
    J Infect Dis; 1998 Dec; 178(6):1555-61. PubMed ID: 9815203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibody based in vitro potency assay as a predictor of antigenic integrity and in vivo immunogenicity of a Respiratory Syncytial Virus post-fusion F-protein based vaccine.
    Djagbare MD; Yu L; Parupudi A; Sun J; Coughlin ML; Rush BS; Sanyal G
    Vaccine; 2018 Mar; 36(12):1673-1680. PubMed ID: 29456016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats.
    Wyde PR; Moore DK; Hepburn T; Silverman CL; Porter TG; Gross M; Taylor G; Demuth SG; Dillon SB
    Pediatr Res; 1995 Oct; 38(4):543-50. PubMed ID: 8559607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linear antigenic and immunogenic regions of the respiratory syncytial virus P protein.
    Leonov SV; Utter G; Waris M; Norrby E
    J Gen Virol; 1994 Jun; 75 ( Pt 6)():1353-9. PubMed ID: 8207401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.